Floatz logo

Elacestrant

Radiation Therapy

Azienda Ospedaliero-Universitaria CareggiSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Radiation Therapy cohort.

Asset / SponsorPhaseRating
Epirubicin
Peking University First Hospital
Phase 2CCC
Axitinib
Peking University First Hospital
Phase 2CCC
Toripalimab
Peking University First Hospital
Phase 2CCC
Cyclophosphamide
Peking University First Hospital
Phase 2CCC
Docetaxel
Peking University First Hospital
N/AD

Same molecule, other indications

Elacestrant is also rated in:

hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
68 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →